Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
10x Genomics, Inc.
Report date July 29, 2022 · Filed August 25, 2022
Section 16 reporting ended · disclosed 2022-08-25. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 02, 2020 Filed Nov 4, 2020 21:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,500 | $135.29 | $202,938.00 |
DisclosureSEC source: 0001209191-20-057066 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,967 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $134.63 to $139.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 21:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,504 | $1.16 | $12,184.64 |
DisclosureSEC source: 0001209191-20-057066 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 16:02 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-20-053571 · doc4.xml · derivative · entry 6 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 664,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · derivative.exercise_date: This option, originally for 800,000 shares, of which 136,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 16:02 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $126.88 | $38,064.00 |
DisclosureSEC source: 0001209191-20-053571 · doc4.xml · nonDerivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 963 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 16:02 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,475 | $125.99 | $437,821.85 |
DisclosureSEC source: 0001209191-20-053571 · doc4.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,263 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $125.81 to $126.13. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 16:02 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 10,725 | $125.48 | $1,345,731.17 |
DisclosureSEC source: 0001209191-20-053571 · doc4.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,738 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $124.81 to $125.80. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 16:02 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,500 | $124.26 | $310,643.00 |
DisclosureSEC source: 0001209191-20-053571 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,463 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $123.76 to $124.72. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 16:02 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001209191-20-053571 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 3,224 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-20-049517 · doc4.xml · derivative · entry 13 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 681,000 Underlying: Class A Common Stock · 3,224 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F11 · derivative.exercise_date: This option, originally for 800,000 shares, of which 119,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 50 | $114.89 | $5,744.50 |
DisclosureSEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 11 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 963 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 150 | $114.10 | $17,115.00 |
DisclosureSEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 10 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,013 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $113.82 to $114.57. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 528 | $113.18 | $59,758.99 |
DisclosureSEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 9 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,163 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $112.82 to $113.655. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,496 | $112.32 | $168,034.61 |
DisclosureSEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 8 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,691 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $111.80 to $112.74. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,000 | $111.33 | $111,327.30 |
DisclosureSEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 7 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,187 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $110.79 to $111.72. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 3,224 | $1.16 | $3,739.84 |
DisclosureSEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 6 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 13,776 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-20-049517 · doc4.xml · derivative · entry 12 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 684,224 Underlying: Class A Common Stock · 13,776 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F10 · derivative.exercise_date: This option, originally for 800,000 shares, of which 115,776 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $115.41 | $57,704.40 |
DisclosureSEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 963 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $115.29 to $115.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,789 | $114.65 | $549,039.22 |
DisclosureSEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,463 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $114.27 to $115.25. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,887 | $113.82 | $670,066.58 |
DisclosureSEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,252 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $113.26 to $114.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,600 | $112.92 | $293,593.04 |
DisclosureSEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,139 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $112.25 to $113.23. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 17:58 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 13,776 | $1.16 | $15,980.16 |
DisclosureSEC source: 0001209191-20-049517 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-20-045147 · doc4.xml · derivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 698,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · derivative.exercise_date: This option, originally for 800,000 shares, of which 102,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,200 | $100.72 | $120,858.96 |
DisclosureSEC source: 0001209191-20-045147 · doc4.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 963 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $100.23 to $101.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 8,342 | $99.47 | $829,817.95 |
DisclosureSEC source: 0001209191-20-045147 · doc4.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,163 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $99.19 to $100.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 7,458 | $98.94 | $737,929.57 |
DisclosureSEC source: 0001209191-20-045147 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,505 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $98.19 to $99.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001209191-20-045147 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · balance_after: Includes 963 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan on May 14, 2020. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:21 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-20-040739 · doc4.xml · derivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 715,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · derivative.exercise_date: This option, originally for 800,000 shares, of which 85,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:21 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 500 | $88.73 | $44,366.00 |
DisclosureSEC source: 0001209191-20-040739 · doc4.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $88.50 to $88.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:21 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 8,900 | $87.94 | $782,707.83 |
DisclosureSEC source: 0001209191-20-040739 · doc4.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $87.49 to $88.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:21 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 7,600 | $87.11 | $662,061.84 |
DisclosureSEC source: 0001209191-20-040739 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,400 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $86.49 to $87.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:21 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001209191-20-040739 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 17:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-20-034163 · doc4.xml · derivative · entry 8 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 732,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · derivative.exercise_date: This option, originally for 800,000 shares, of which 68,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 17:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,000 | $81.92 | $163,844.00 |
DisclosureSEC source: 0001209191-20-034163 · doc4.xml · nonDerivative · entry 7 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $81.74 to $82.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 17:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,900 | $81.39 | $398,801.20 |
DisclosureSEC source: 0001209191-20-034163 · doc4.xml · nonDerivative · entry 6 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $80.74 to $81.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 17:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,500 | $80.05 | $200,132.00 |
DisclosureSEC source: 0001209191-20-034163 · doc4.xml · nonDerivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,900 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $79.66 to $80.65. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 17:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,500 | $79.14 | $197,845.00 |
DisclosureSEC source: 0001209191-20-034163 · doc4.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,400 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $78.65 to $79.64. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 17:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,400 | $78.06 | $265,419.64 |
DisclosureSEC source: 0001209191-20-034163 · doc4.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,900 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $77.62 to $78.46. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 17:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,700 | $77.17 | $131,182.03 |
DisclosureSEC source: 0001209191-20-034163 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,300 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $76.60 to $77.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 17:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001209191-20-034163 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| May 01, 2020 Filed May 5, 2020 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-20-027168 · doc4.xml · derivative · entry 6 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 749,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · derivative.exercise_date: This option, originally for 800,000 shares, of which 51,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 01, 2020 Filed May 5, 2020 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 300 | $79.23 | $23,769.00 |
DisclosureSEC source: 0001209191-20-027168 · doc4.xml · nonDerivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $79.20 to $79.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 01, 2020 Filed May 5, 2020 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,200 | $78.66 | $330,370.32 |
DisclosureSEC source: 0001209191-20-027168 · doc4.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $78.16 to $79.12. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 01, 2020 Filed May 5, 2020 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,695 | $77.57 | $286,633.71 |
DisclosureSEC source: 0001209191-20-027168 · doc4.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $77.13 to $78.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 01, 2020 Filed May 5, 2020 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 8,805 | $76.63 | $674,696.33 |
DisclosureSEC source: 0001209191-20-027168 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,195 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $76.13 to $77.09. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 01, 2020 Filed May 5, 2020 16:51 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 17,000 | $1.16 | $19,720.00 |
DisclosureSEC source: 0001209191-20-027168 · doc4.xml · nonDerivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 16:44 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 90,667 | $0.00 Strike: $74.58 | $0.00 |
DisclosureSEC source: 0001209191-20-025437 · doc4.xml · derivative · entry 1 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,667 Underlying: Class A Common Stock · 90,667 shares Expires 2030-04-21 F1 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one forty-eighth of the shares on May 1, 2020 and each month thereafter, subject to the reporting person continuing as a service provider through each such date. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-20-023278 · doc4.xml · derivative · entry 5 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 766,000 Underlying: Class A Common Stock · 17,000 shares Expires 2027-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · derivative.exercise_date: This option, originally for 800,000 shares, of which 34,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 400 | $59.62 | $23,848.12 |
DisclosureSEC source: 0001209191-20-023278 · doc4.xml · nonDerivative · entry 4 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $59.38 to $59.80. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 7,789 | $58.33 | $454,318.35 |
DisclosureSEC source: 0001209191-20-023278 · doc4.xml · nonDerivative · entry 3 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $58.02 to $58.96. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:10 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 8,811 | $57.75 | $508,839.66 |
DisclosureSEC source: 0001209191-20-023278 · doc4.xml · nonDerivative · entry 2 CRUTCHFIELD BRADFORD · CIK 0001246406 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,189 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $57.02 to $58.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.